RecruitingPhase 3NCT04161768

Norfloxacin With Itopride Versus Norfloxacin in Secondary Prophylaxis of Spontaneous Bacterial Peritonitis

Comparative Study of Norfloxacin Versus Norfloxacin With Itopride in Secondary Prophylaxis of Spontaneous Bacterial Peritonitis

Sponsor

Tanta University

Enrollment

80 participants

Start Date

Dec 1, 2018

Study Type

INTERVENTIONAL

Conditions

Spontaneous bacterial peritonitis

Summary

Norfloxacin versus Norfloxacin with Itopride in Secondary Prophylaxis of Spontaneous Bacterial Peritonitis

Eligibility

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Itopride and a drug called Norfloxacin for people with spontaneous bacterial peritonitis. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGNorfloxacin

Norfloxacin 400 mg daily

DRUGItopride

Itopride 50 mg three times daily

Locations(1)

Sherief Abd-Elsalam

Tanta, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04161768

Related Trials

Efficacy of Conventional Dose Protocol vs Low Dose Protocol Albumin Use in Patients With Cirrhosis and High Risk Spontaneous Bacterial Peritonitis

NCT060262671 location

Oral Gemifloxacin Versus Intravenous Cefotaxime in Treatment of Spontaneous Bacterial Peritonitis

NCT041680991 location